SILVER SPRING, Md.,
April 29, 2014 /PRNewswire/
-- Pharmagen, Inc. (OTCQB: PHRX) (the "Company" or
"Pharmagen") today announced that Boyd
Relac has been appointed as its Chief Operating Officer
("COO"). Boyd brings with him over 20 years of experience including
holding notable senior level positions with such companies as
Dentsply International, Patterson Companies, Maly's Midwest and
most recently L'Oreal/SalonCentric. Boyd also formed and honed his
leadership skills as a U.S. Army Officer in elite airborne and
special operations units. Boyd was awarded the Bronze Star
Medal for meritorious service during Operation Desert Storm and
earned 3 Meritorious Service Medals for leadership in command and
staff positions of special operations units.
"I have known and worked with Boyd over the past 10 years," says
Richard Wolpow, Pharmagen's Chairman
and previous Interim-COO. "There was a short list of
candidates to take over the COO role, and Boyd was on the top of
that list. Boyd has the perfect mix of that entrepreneurial spirit,
large corporate experience and military commitment to excellence.
Boyd will be an integral part to the success of the Company's long
term consolidation plan that has been in the works since this past
October. I am proud to have him as part of the Pharmagen
Team," Wolpow concluded.
From 1997 to 2008, Mr. Relac held various positions of
increasing responsibility in the dental industry at Dentsply
International and Patterson Dental. He built a reputation for
impactful revenue growth as a result of his ability to execute on
the detailed strategic sales and marketing plans he wrote for both
companies. In 2008 he transitioned to the professional beauty
industry as a VP/GM initially executing a turn-around and quick
sale of a privately held $90MM distributor to L'Oreal. At L'Oreal
he again lead above-budgeted growth progressing from Regional Vice
President leading sales execution and integrating acquisitions in
the Midwest, to the national sales leadership role where he
initially served as Vice President, Sales and Strategic Development
evolving to focus his energies on integrating nine acquisitions
plus restructuring sales teams.
"When I first spoke with Richard about the Company and its
consolidation plan I immediately appreciated the role and
responsibility that Pharmagen has in contributing to the safety and
efficacy of sterile and non-sterile compounded pharmaceuticals in
the U.S. today, not to overshadow the void Pharmagen fills in
finding and sourcing scarce pharmaceuticals for hospitals every
day. As I began to understand the vision for Pharmagen and met
the dedicated professionals on the team, I quickly realized the
opportunity as COO was a perfect fit for my experience and desire
to serve a company and its emerging customer base. I am already
proud to be associated with a company such as Pharmagen because of
the commitment we have to the highest quality that cGMP compliance
brings to the forefront. It's already a rewarding experience and we
are just getting started!" stated Mr. Relac.
About Pharmagen
Pharmagen, Inc. ("Pharmagen"), and wholly owned
subsidiaries and operating divisions Pharmagen Laboratories, Inc.,
Pharmagen Distribution, LLC and Pharmagen Nutraceuticals, Inc.
offers innovative solutions to the nations sterile pharmaceutical
crisis. With a multi-solution approach, Pharmagen is helping
to meet the demand of the health provider market through
independent wholesale, compounding, and IT solutions. Nationally
focused, Pharmagen is a distributor of specialty drugs, compounding
and admix pharmacy and producer of over-the-counter ("OTC") branded
multivitamins. Pharmagen currently functions as a just-in-time
source of supply for hospitals for those products that are
hard-to-find.
Contact: 888-264-4597 or info@pharmagenrx.com
Follow Us on Twitter: @pharmagenrx or
The Drug Shortage Report
http://drugshortagereport.blogspot.com/
Safe Harbor Statement
Information in this document constitute forward-looking
statements or statements which may be deemed or construed to be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. The words
"forecast", "anticipate", "estimate", "project", "intend",
"expect", "should", "believe", and similar expressions are intended
to identify forward-looking statements. These forward-looking
statements involve, and are subject to known and unknown risks,
uncertainties and other factors which could cause Pharmagen actual
results, performance (financial or operating) or achievements to
differ from the future results, performance (financial or
operating) or achievements expressed or implied by such
forward-looking statements. The risks, uncertainties and other
factors are more fully discussed in Pharmagen's filings with the
U.S. Securities and Exchange Commission. All forward-looking
statements attributable to Pharmagen herein are expressly qualified
in their entirety by the above-mentioned cautionary
statement. Pharmagen disclaims any obligation to update
forward-looking statements contained in this estimate, except as
may be required by law.
SOURCE Pharmagen, Inc.
